002424：已满足撤销其他风险警示的条件

Core Viewpoint - ST Bailin (002424) has applied to revoke the other risk warning on its stock, stating that internal control deficiencies have been rectified and that it meets the requirements for revocation [1][3]. Group 1: Company Actions and Compliance - In 2023, ST Bailin received a negative opinion in its internal control audit report from Tianjian Accounting Firm, leading to the implementation of other risk warnings by the Shenzhen Stock Exchange [3]. - The company has undertaken extensive internal control rectification and quality improvement efforts under the leadership of its board, aiming for "removal of the warning and turnaround" as a core task for 2024 [3][4]. - A special verification opinion from Guizhou Beidouxing Law Firm confirmed that the issues leading to the negative opinion have been resolved, and there are no new circumstances warranting risk warnings [4]. Group 2: Financial Performance - In 2024, ST Bailin achieved operating revenue of 3.825 billion yuan and a net profit of 33.62 million yuan, successfully turning a profit [4]. - The company is focusing on its "14th Five-Year" development plan, emphasizing large-scale manufacturing, multi-channel marketing, major product innovation, and industry chain integration to overcome challenges such as high social inventory of "four types of drugs" [4]. Group 3: Product Portfolio and Market Position - ST Bailin is engaged in the research, production, and sales of苗药 (Miao medicine), with key products including Yindan Xinnaotong soft capsules and Kesu Ting syrup, which hold significant market shares in cardiovascular, cough, cold, and pediatric medicine sectors [4]. - The company is actively expanding its integrated Miao medicine project centered around Tang Ning Tong Luo, aiming to broaden its market reach [4].